← Back to all signals
RESEARCH PAPER ANALYSIS

Choices of morbidity outcomes and concentration-response functions for health risk assessment of long-term exposure to air pollution.

AI interpretation is pending for this paper.

Open original publication →
PMID39045486
JournalEnvironmental epidemiology (Philadelphia, Pa.)
Publication Date2024-06-25
Ingested2026-08-02 12:02 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Air pollution health risk assessment (HRA) has been typically conducted for all causes and cause-specific mortality based on concentration-response functions (CRFs) from meta-analyses that synthesize the evidence on air pollution health effects. There is a need for a similar systematic approach for HRA for morbidity outcomes, which have often been omitted from HRA of air pollution, thus underestimating the full air pollution burden. We aimed to compile from the existing systematic reviews and meta-analyses CRFs for the incidence of several diseases that could be applied in HRA. To achieve this goal, we have developed a comprehensive strategy for the appraisal of the systematic reviews and meta-analyses that examine the relationship between long-term exposure to particulate matter with an aerodynamic diameter smaller than 2.5 µm (PM2.5), nitrogen dioxide (NO2), or ozone (O3) and incidence of various diseases. METHODS: To establish the basis for our evaluation, we considered the causality determinations provided by the US Environmental Protection Agency Integrated Science Assessment for PM2.5, NO2, and O3. We developed a list of pollutant/outcome pairs based on these assessments and the evidence of a causal relationship between air pollutants and specific health outcomes. We conducted a comprehensive literature search using two databases and identified 75 relevant systematic reviews and meta-analyses for PM2.5 and NO2. We found no relevant reviews for long-term exposure to ozone. We evaluated the reliability of these studies using an adaptation of the AMSTAR 2 tool, which assesses various characteristics of the reviews, such as literature search, data extraction, statistical analysis, and bias evaluation. The tool's adaptation focused on issues relevant to studies on the health effects of air pollution. Based on our assessment, we selected reviews that could be credible sources of CRF for HRA. We also assessed the confidence in the findings of the selected systematic reviews and meta-analyses as the sources of CRF for HRA. We developed specific criteria for the evaluation, considering factors such as the number of included studies, their geographical distribution, heterogeneity of study results, the statistical significance and precision of the pooled risk estimate in the meta-analysis, and consistency with more recent studies. Based on our assessment, we classified the outcomes into three lists: list A (a reliable quantification of health effects is possible in an HRA), list B+ (HRA is possible, but there is greater uncertainty around the reliability of the CRF compared to those included on list A), and list B- (HRA is not recommended because of the substantial uncertainty of the CRF). RESULTS: In our final evaluation, list A includes six CRFs for PM2.5 (asthma in children, chronic obstructive pulmonary disease, ischemic heart disease events, stroke, hypertension, and lung cancer) and three outcomes for NO2 (asthma in children and in adults, and acute lower respiratory infections in children). Three additional outcomes (diabetes, dementia, and autism spectrum disorders) for PM2.5 were included in list B+. Recommended CRFs are related to the incidence (onset) of the diseases. The International Classification of Diseases, 10th revision codes, age ranges, and suggested concentration ranges are also specified to ensure consistency and applicability in an HRA. No specific suggestions were given for ozone because of the lack of relevant systematic reviews. CONCLUSION: The suggestions formulated in this study, including CRFs selected from the available systematic reviews, can assist in conducting reliable HRAs and contribute to evidence-based decision-making in public health and environmental policy. Future research should continue to update and refine these suggestions as new evidence becomes available and methodologies evolve.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 [The role of neuroprotection in treating oculomotor neuropathy in a child following endoscopic cystocisternostomy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 57.6 2 Rivaroxaban prophylaxis and catheter-related thrombosis risk in ambulatory gynecological cancer patients: a retrospective cohort study. Thrombosis journal 76.9 3 Mesenchymal transition as a potential mechanism of late immune evasion in neuroblastoma: a case of late relapse after allogeneic hematopoietic stem cell transplantation. World journal of surgical oncology 88.37 4 Gold Nanoparticles in Retinoblastoma: A Promising Approach for Diagnosis and Treatment. Ocular oncology and pathology 76.5 5 Pars Plana Vitrectomy for Retinal Detachment or Vitreous Haemorrhage after Retinoblastoma Regression: A 20-Year Single-Centre Experience. Ocular oncology and pathology 63.1 6 A Novel Protein Corona-Based Secretome Profiling Assisting Cell Multiomics Analysis. Analytical chemistry 49.7 7 Trefoil Family Factor 1 Expression in the Indian Cohort of Treatment-Naïve Retinoblastoma. Ocular oncology and pathology 66.14 8 mTOR inhibitor everolimus versus conventional chemotherapy in pediatric low-grade gliomas. American journal of cancer research 83.3 9 The scPagwas analysis of single-cell sequencing combined with Bayesian deconvolution with SMR Reveals Tumor Heterogeneity and Predicts Immunotherapy Response in Neuroblastoma. Journal of Cancer 67.34 10 Early Prediction of Cardiomyopathy in Pediatric Cancer Survivors Using Echocardiographic Video-Based Deep Learning. Echocardiography (Mount Kisco, N.Y.) 57.5 11 Novel Compound Heterozygous RECQL4 Pathogenic Variants and Associated Phenotypes in a Chinese Patient With Rothmund-Thomson Syndrome: Case Report and Literature Review. Molecular genetics & genomic medicine 47.5 12 Self-Conscious Emotions and Social Isolation Among Young Adult Cancer Survivors. Psycho-oncology 66.0 13 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO open 71.84 14 Fertility preservation counselling in women with cancer: knowledge, preferences, and unmet needs from a cross-sectional survey. Frontiers in endocrinology 66.1 15 Risk prediction model for pegaspargase-associated severe coagulopathy and blood product costs: a single-center retrospective cohort study. Frontiers in pharmacology 63.9 16 The relationship between symptoms of adenomyosis and current ultrasonographic diagnostic criteria. Frontiers in endocrinology 62.4 17 Feasibility of exercise training to address corticosteroid-induced changes in adolescents aged 10+ with lymphoma or leukemia during the first eight weeks of treatment: a pilot study. Frontiers in pediatrics 82.84 18 A predictive model for cytarabine syndrome-associated febrile episodes in children with acute lymphoblastic leukemia. Frontiers in pediatrics 67.4 19 The role of personalised medicine in treating high-risk neuroblastoma in paediatric patients. Oncology reviews 74.0 20 Incidence, severity, and risk factors of platinum-induced ototoxicity in pediatric oncology patients: A multi-center retrospective study. International journal of pediatric otorhinolaryngology 80.72 21 Intracranial Extension of Pott's Puffy Tumor in a Child: CT and MRI Findings. Revista da Sociedade Brasileira de Medicina Tropical 28.5 22 Detecting Isolated Multifocal Leptomeningeal Metastases With 18F-MFBG PET/CT in a Pediatric Patient With High-risk Neuroblastoma. Clinical nuclear medicine 56.4 23 Unusual Isolated Thymic Relapse of Neuroblastoma Detected By 123I-mIBG Scintigraphy in a Pediatric Patient. Clinical nuclear medicine 55.62 24 A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-FDG, 68Ga-DOTATATE, and 18F-MFBG in a Pediatric Neuroblastoma Patient. Clinical nuclear medicine 57.1 25 Clinical Diagnostic and Prognostic Evaluation of miR-136-5p in Children with Severe Pneumonia: A Case-Control and Cohort Study. Journal of visualized experiments : JoVE 70.8 26 Parents' and health professionals' perspectives on supporting physical activity among children undergoing cancer treatment: A qualitative interview study. European journal of oncology nursing : the official journal of European Oncology Nursing Society 62.74 27 Tests of the testes: markers of testicular function after treatment for pediatric hematological malignancies. The Journal of clinical endocrinology and metabolism 50.74 28 Checkpoint blockade before allogeneic transplantation in pediatric lymphoma warrants a dedicated safety strategy. Comment on: "Immune checkpoint therapy in pediatric and adolescent lymphomas". Haematologica 52.74 29 Forty-Two Cases of Pediatric Giant Cell Tumor of Bone: Insights From a 25-Year Multi-Institutional Cohort. Journal of pediatric orthopedics 63.1 30 Impact of Childbearing and Breastfeeding on Breast Density Change, and Subsequent Breast Cancer Risk in Postmenopausal Women: A Mediation Analysis. International journal of cancer 58.4 31 Neuropathological findings in 2068 individuals with drug-resistant epilepsy based on updated classification systems: A multicenter retrospective cohort study from China. Epilepsia 65.16 32 Clinical Impact of Busulfan Pharmacokinetic Monitoring in Pediatric Allogeneic Transplants: Perspectives from A Transplant Center in A Low- and Middle- Income Country. Pediatric hematology and oncology 63.4
PATIENT-FRIENDLY SUMMARY

Choices of morbidity outcomes and concentration-response functions for health risk assessment of long-term exposure to air pollution.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic